Granted Patent B2

US 9,464,276 · App. 14/628,513 · Granted Oct 11, 2016

Inventors: Gale Smith (Gaithersburg, MD); Yingyun Wu (Clarksburg, MD); Michael Massare (Mt. Airy, MD); Peter Pushko (Frederick, MD); Margaret Nathan (Montgomery Village, MD); Thomas Kort (Germantown, MD); Robin Robinson (Gaithersburg, MD)

Assignee: Novavax, Inc.

C12N7/00A61K39/12C07K14/005C12N9/2402C12Y302/01018A61K2039/5258A61K2039/55505A61K2039/55555C07K2319/01C07K2319/03C12N2710/14143C12N2760/16122C12N2760/16123C12N2760/16134C12N2760/16151C12N2760/16171C12N2760/16222C12N2760/16223C12N2760/16251C12N2770/20022C12N2770/20023C12N2770/20051C12N2800/22

Abstract

Claims (17)

1. A method of increasing production of a VLP comprising expressing a mutated influenza M1 protein, an influenza HA protein, and an influenza NA protein in a host cell,

wherein the mutated influenza M1 protein comprises an Arginine to Lysine mutation at the position corresponding to position 101 of SEQ ID NO: 49, wherein increased VLP release from the host cell is obtained with the M1 protein having the Lysine compared to VLP release obtained with an M1 protein having Arginine at the position corresponding to position 101 of SEQ ID NO: 49.

2. The method of claim 1 wherein the influenza M1 protein is derived from an avian influenza virus strain.

3. The method of claim 1 , wherein the HA and NA proteins are derived from an avian influenza virus.

4. The method of claim 1 , wherein the HA and NA proteins are derived from a seasonal influenza virus.

5. The method of claim 4 , wherein the seasonal influenza virus is a type A influenza virus.

6. The method of claim 4 , wherein the seasonal influenza virus is a type B influenza virus.

7. The method of claim 1 , wherein the HA protein exhibits hemagglutinin activity.

8. The method of claim 1 , wherein the NA protein exhibits neuraminidase activity.

9. The method of claim 1 , wherein the HA protein exhibits hemagglutinin activity and the NA protein exhibits neuraminidase activity.

10. The method of claim 1 , wherein at least one of the HA protein and the NA protein is a chimeric protein.

11. The method of claim 10 , wherein the chimeric protein is a chimeric HA protein comprising the external domain of a non-avian influenza HA fused to the transmembrane domain of an avian HA protein.

12. The method of claim 11 , wherein the chimeric HA protein further comprises a cytoplasmic terminal domain of an avian HA protein.

13. The method of claim 10 , wherein the chimeric protein is a chimeric NA protein comprising the external domain of a non-avian influenza NA fused to the transmembrane domains of an avian NA protein.

14. The method of claim 13 , wherein the chimeric NA protein further comprises a cytoplasmic terminal domain of an avian NA protein.

15. The method of claim 1 wherein the host cell is an insect cell.

16. The method of claim 15 wherein the insect cell is an Sf9 cell.

Assignments (2)

Continuity (16)